Cambridge Cognition Holdings (GB:COG) has released an update.
Cambridge Cognition Holdings PLC’s spin-out, Monument Therapeutics, has secured £1.5 million in funding and grants for the clinical development of a promising schizophrenia treatment. The investment will fuel the commencement of clinical trials for MT1988, a novel drug aimed at treating cognitive impairments in schizophrenia patients. The funding round, supported by leading angel investor networks, showcases confidence in Monument’s innovative approach to precision medicine in psychiatry and neurology.
For further insights into GB:COG stock, check out TipRanks’ Stock Analysis page.
